Isabelle Ray-Coquard

Summary

Publications

  1. pmc Pazopanib for the treatment of soft-tissue sarcoma
    Pierre Heudel
    Department of Medical Oncology, Leon Berard Center, Lyon, France
    Clin Pharmacol 4:65-70. 2012
  2. ncbi request reprint Biology of ovarian cancer and trabectedin mechanism of action
    Isabelle Ray-Coquard
    Medical Oncology, Centre Leon Berard, Lyon, France
    Future Oncol 9:11-7. 2013
  3. pmc Everolimus as second- or third-line treatment of advanced endometrial cancer: ENDORAD, a phase II trial of GINECO
    I Ray-Coquard
    Department of Medical Oncology, Centre Leon Berard, 28 rue Laennec, Lyon Cedex 08, France
    Br J Cancer 108:1771-7. 2013
  4. doi request reprint Effect of the MDM2 antagonist RG7112 on the P53 pathway in patients with MDM2-amplified, well-differentiated or dedifferentiated liposarcoma: an exploratory proof-of-mechanism study
    Isabelle Ray-Coquard
    Centre Leon Berard, Lyon, France EAM 4128 Santé Individu Société, Universite Claude Bernard Lyon I, Lyon, France
    Lancet Oncol 13:1133-40. 2012
  5. pmc Sarcoma: concordance between initial diagnosis and centralized expert review in a population-based study within three European regions
    I Ray-Coquard
    University Lyon, EAM 4129 Health Individual Society, Hotel Dieu, Lyon, France
    Ann Oncol 23:2442-9. 2012
  6. pmc Clinicians' adherence versus non adherence to practice guidelines in the management of patients with sarcoma: a cost-effectiveness assessment in two European regions
    Lionel Perrier
    University of Lyon, F 69007 Lyon, France
    BMC Health Serv Res 12:82. 2012
  7. doi request reprint [PAIR-gynaecology: multi/interdisciplinary for gynecologic cancer research. Problems needed to be resolved]
    Isabelle Ray-Coquard
    Université Lyon I, Centre Leon Berard, France
    Bull Cancer 99:479-98. 2012
  8. doi request reprint Management of anemia in advanced breast and lung cancer patients in daily practice: results of a French survey
    Isabelle Ray-Coquard
    Departement d Oncologie Medicale, Centre Leon Berard, Lyon, France
    Adv Ther 29:124-33. 2012
  9. doi request reprint CD4 lymphopenia to identify end-of-life metastatic cancer patients
    Julien Peron
    Universite de Lyon, Lyon, France Université Lyon 1, Villeurbanne, France
    Eur J Cancer 49:1080-9. 2013
  10. doi request reprint Imatinib mesilate for the treatment of gastrointestinal stromal tumour
    Philippe A Cassier
    unité de jour d oncologie médicale multidisciplinaire, Pavillon E, Hopital Edouard Herriot, 5 Place d Arsonval, 69003, Lyon, France
    Expert Opin Pharmacother 9:1211-22. 2008

Detail Information

Publications62

  1. pmc Pazopanib for the treatment of soft-tissue sarcoma
    Pierre Heudel
    Department of Medical Oncology, Leon Berard Center, Lyon, France
    Clin Pharmacol 4:65-70. 2012
    ..In comparison with sunitinib or sorafenib, pazopanib has a similar toxicity profile and is generally well tolerated. This review details the development of this new therapeutic class in the treatment of metastatic soft-tissue sarcomas...
  2. ncbi request reprint Biology of ovarian cancer and trabectedin mechanism of action
    Isabelle Ray-Coquard
    Medical Oncology, Centre Leon Berard, Lyon, France
    Future Oncol 9:11-7. 2013
    ..g., a reduction of IL-6). Thus, trabectedin is an agent with mechanisms of action especially appropriate for targeting key processes in the biology of ovarian cancer. ..
  3. pmc Everolimus as second- or third-line treatment of advanced endometrial cancer: ENDORAD, a phase II trial of GINECO
    I Ray-Coquard
    Department of Medical Oncology, Centre Leon Berard, 28 rue Laennec, Lyon Cedex 08, France
    Br J Cancer 108:1771-7. 2013
    ..Preclinical data suggest the oral mammalian target of rapamycin inhibitor everolimus may provide clinical benefit in these patients...
  4. doi request reprint Effect of the MDM2 antagonist RG7112 on the P53 pathway in patients with MDM2-amplified, well-differentiated or dedifferentiated liposarcoma: an exploratory proof-of-mechanism study
    Isabelle Ray-Coquard
    Centre Leon Berard, Lyon, France EAM 4128 Santé Individu Société, Universite Claude Bernard Lyon I, Lyon, France
    Lancet Oncol 13:1133-40. 2012
    ..We report a proof-of-mechanism study of RG7112, a small-molecule MDM2 antagonist, in patients with chemotherapy-naive primary or relapsed well-differentiated or dedifferentiated MDM2-amplified liposarcoma who were eligible for resection...
  5. pmc Sarcoma: concordance between initial diagnosis and centralized expert review in a population-based study within three European regions
    I Ray-Coquard
    University Lyon, EAM 4129 Health Individual Society, Hotel Dieu, Lyon, France
    Ann Oncol 23:2442-9. 2012
    ..The contribution of second opinion (SO) to improve diagnostic accuracy has been suggested for sarcoma but has never been established in population-based studies...
  6. pmc Clinicians' adherence versus non adherence to practice guidelines in the management of patients with sarcoma: a cost-effectiveness assessment in two European regions
    Lionel Perrier
    University of Lyon, F 69007 Lyon, France
    BMC Health Serv Res 12:82. 2012
    ....
  7. doi request reprint [PAIR-gynaecology: multi/interdisciplinary for gynecologic cancer research. Problems needed to be resolved]
    Isabelle Ray-Coquard
    Université Lyon I, Centre Leon Berard, France
    Bull Cancer 99:479-98. 2012
    ....
  8. doi request reprint Management of anemia in advanced breast and lung cancer patients in daily practice: results of a French survey
    Isabelle Ray-Coquard
    Departement d Oncologie Medicale, Centre Leon Berard, Lyon, France
    Adv Ther 29:124-33. 2012
    ....
  9. doi request reprint CD4 lymphopenia to identify end-of-life metastatic cancer patients
    Julien Peron
    Universite de Lyon, Lyon, France Université Lyon 1, Villeurbanne, France
    Eur J Cancer 49:1080-9. 2013
    ..Cancer patients with CD4 lymphopenia have an increased risk of severe toxicity after administration of cytotoxic chemotherapy. The impact of CD4 lymphopenia on long term overall survival (OS) of cancer patients was explored in this work...
  10. doi request reprint Imatinib mesilate for the treatment of gastrointestinal stromal tumour
    Philippe A Cassier
    unité de jour d oncologie médicale multidisciplinaire, Pavillon E, Hopital Edouard Herriot, 5 Place d Arsonval, 69003, Lyon, France
    Expert Opin Pharmacother 9:1211-22. 2008
    ..Imatinib mesilate, which was approved in 2002 for the treatment of patients with advanced GIST, has dramatically changed the course of the disease...
  11. ncbi request reprint Prospective multicentric randomized phase III study of imatinib in patients with advanced gastrointestinal stromal tumors comparing interruption versus continuation of treatment beyond 1 year: the French Sarcoma Group
    Jean Yves Blay
    Unité INSERM U590 Centre Léon Bérard and Université Claude Bernard Lyon I and Hopital Edouard Herriot, Lyon, France
    J Clin Oncol 25:1107-13. 2007
    ..Imatinib is the standard treatment of advanced GI stromal tumors (GISTs). It is not known whether imatinib may be stopped in patients in whom disease is controlled...
  12. ncbi request reprint Emerging drugs for the treatment of soft tissue sarcomas
    Philippe A Cassier
    Unité de Jour Oncologie Médicale Multidisciplinaire, Hopital Edouard Herriot, Lyon, France
    Expert Opin Emerg Drugs 12:139-53. 2007
    ..This review summarises treatment strategies in the context of advanced disease and discusses new compounds being developed for patients with soft tissue sarcomas...
  13. doi request reprint [Clinical Practice guidelines for the use of erythropoiesis-stimulating agents (ESA: epoetin alfa, epoetin bêta, darbepoetin) in anaemic patients with cancer: 2007 update (summary report)]
    Isabelle Ray-Coquard
    Centre Leon Berard, Lyon
    Bull Cancer 95:433-41. 2008
    ..This article presents a short version of the Recommendations updated in 2007...
  14. doi request reprint Chemotherapy for metastatic breast cancer. Comparison of clinical practice and cost of drugs in two cohorts of patients: 1994-1998 and 2003-2006
    Guillaume Galy
    Department of Pharmacy, Centre Leon Berard, Lyon, 69008, France
    Breast Cancer Res Treat 128:187-95. 2011
    ..56; P = 0.0002). New chemotherapeutic agents induced a significant cost increase over time. The limited size and heterogeneity of our cohort do not allow any conclusion concerning their impact on survival...
  15. ncbi request reprint [Prognostic factors for febrile neutropenia]
    Isabelle Ray-Coquard
    Centre Leon Berard, 28, rue Laennec, 69008 Lyon, France
    Bull Cancer 93:501-6. 2006
    ..Research in quantifying the risk of neutropenic complications may make it possible in the near future to target patients at greater risk with appropriate preventive strategies, thereby maximizing the benefits and minimizing the costs...
  16. doi request reprint Sorafenib in patients with progressive epithelioid hemangioendothelioma: a phase 2 study by the French Sarcoma Group (GSF/GETO)
    Christine Chevreau
    Department of Medical Oncology, Claudius Regaud Institute, Toulouse, France
    Cancer 119:2639-44. 2013
    ..There is no standard treatment for progressive epithelioid hemangioendothelioma (EHE). To investigate the significant vascularization of EHE, the activity/toxicity of sorafenib in patients with progressive EHE was explored...
  17. pmc Long-term outcome and effect of maintenance therapy in patients with advanced sarcoma treated with trabectedin: an analysis of 181 patients of the French ATU compassionate use program
    Jean Yves Blay
    Centre Leon Berard, Lyon, France
    BMC Cancer 13:64. 2013
    ..The long term outcome of advanced sarcoma patients treated with trabectedin outside of clinical trials and the utility of maintenance treatment has not been reported...
  18. doi request reprint Multidisciplinarity and medical decision, impact for patients with cancer: sociological assessment of two tumour committees' organization
    Patrick Castel
    Centre Leon Berard, Lyon, France
    Bull Cancer 99:E34-42. 2012
    ..In the present study, we evaluated the organization of two multidisciplinary committees, one for breast cancer and one for sarcoma, in a French Comprehensive Cancer Centre...
  19. doi request reprint Therapeutic pipeline for soft-tissue sarcoma
    Philippe A Cassier
    Departement de Medecine, Centre Leon Berard, 69008 Lyon, France
    Expert Opin Pharmacother 12:2479-91. 2011
    ..After the initial success of imatinib in gastrointestinal stromal tumors, several other compounds have shown promising activity in some but not all subgroups of sarcoma...
  20. ncbi request reprint Novel approaches to gastrointestinal stromal tumors resistant to imatinib and sunitinib
    Philippe A Cassier
    Conticanet Network of Excellence LSH 060188, Département de Médicine, Centre Leon Berard, 28 rue Laennec, 69008 Lyon, France
    Curr Gastroenterol Rep 10:555-61. 2008
    ..This article reviews the current knowledge regarding IM and SU resistance in GIST, as well as the available options for the management of GIST resistant to IM and SU...
  21. pmc Lymphopenia as a prognostic factor for overall survival in advanced carcinomas, sarcomas, and lymphomas
    Isabelle Ray-Coquard
    Université de Lyon Centre Léon Bérard, Department of Medical Oncology and EA SIS 4128, Lyon, France
    Cancer Res 69:5383-91. 2009
    ..48; 95% CI, 1.03-2.1) along with IPI. Our findings show that lymphopenia is an independent prognostic factor for overall and progression-free survival in several cancers...
  22. doi request reprint A phase 2 trial of whole-brain radiotherapy combined with intravenous chemotherapy in patients with brain metastases from breast cancer
    Philippe A Cassier
    Multidisciplinary Medical Oncology Day Unit, Edouard Herriot Hospital, Lyon, France
    Cancer 113:2532-8. 2008
    ..A study was conducted to determine the efficacy, tolerability, and safety of concurrent cisplatin and vinorelbine chemotherapy and radiotherapy in patients with previously untreated brain metastases from breast cancer...
  23. pmc Phase I combination study of trabectedin and doxorubicin in patients with soft-tissue sarcoma
    Jean Yves Blay
    CONTICANET and UJOMM Hôpital Edouard Herrot, Centre Leon Berard, Lyon, France
    Clin Cancer Res 14:6656-62. 2008
    ..Blood was collected during cycle 1 for pharmacokinetic analyses. Adverse events, tumor response, and survival were assessed...
  24. doi request reprint [To answer rare cancer issues. Geographical analysis of EMS sarcoma cohort in the Rhône-Alpes region]
    Yohan Fayet
    université Jean Moulin Lyon 3, EA Santé Individu Société, 18, rue Chevreul 69007 Lyon, France, Centre Léon Bérard Lyon, EA Santé Individu Société, 28, rue Laennec, 69008 Lyon, France
    Bull Cancer 101:127-36. 2014
    ..In the scope of an interdisciplinary collaboration, the geographical approach develops some hypothesis for rare cancers research, which must be tested by other larger scale studies. ..
  25. doi request reprint Efficacy of trabectedin for advanced sarcomas in clinical trials versus compassionate use programs: analysis of 92 patients treated in a single institution
    Jerome Fayette
    Department of Medicine, Unite INSERM, Centre Leon Berard, Lyon, France
    Anticancer Drugs 21:113-9. 2010
    ..The safety and tolerability of trabectedin shown in clinical trials is confirmed for patients in real-life situation treated in compassionate use programs, but its benefit is higher for patients with performance status 0-1...
  26. pmc Prognostic value of the expression of C-Chemokine Receptor 6 and 7 and their ligands in non-metastatic breast cancer
    Philippe A Cassier
    Department of Medecine, Centre Leon Berard, Lyon, France
    BMC Cancer 11:213. 2011
    ..Chemokines CCL19, CCL20 and CCL21 and their receptors CCR6 and CCR7, were assessed as potential biomarkers of metastatic dissemination in primary breast cancer...
  27. pmc Outcome of patients with advanced solitary fibrous tumors: the Centre Léon Bérard experience
    Alice Levard
    Department of Medical Oncology, Centre Leon Berard, 28 rue Laennec, 69008, Lyon, France
    BMC Cancer 13:109. 2013
    ..Data on the management of patients with advanced SFT is scarce: chemotherapy has been described as ineffective, while recent data suggests that anti-angiogenic therapies may be more efficient...
  28. doi request reprint A role for maintenance therapy in managing sarcoma
    Isabelle Ray-Coquard
    Département d Oncologie Médicale and EAM Santé Individu Société, Centre Leon Berard, 28 rue Laennec, F 69373 Lyon Cedex 08, France
    Cancer Treat Rev 38:368-78. 2012
    ..One such mTOR inhibitor, ridaforolimus (AP23573, MK-8669), is currently being evaluated in patients with advanced bone and STS in the ongoing Sarcoma mUlti-Center Clinical Evaluation of the Efficacy of riDaforolimus (SUCCEED) trial...
  29. pmc Validation of prognostic scores for survival in cancer patients beyond first-line therapy
    Olivier Tredan
    Universite de Lyon, Centre Leon Berard, Department of Medical Oncology, 28 rue Laennec, 69008 Lyon, France
    BMC Cancer 11:95. 2011
    ..We aimed to validate prognostic scores for survival in patients undergoing chemotherapy for advanced or metastatic cancer after first-line treatment...
  30. pmc Can treatment with Cocculine improve the control of chemotherapy-induced emesis in early breast cancer patients? A randomized, multi-centered, double-blind, placebo-controlled Phase III trial
    David Perol
    Centre Leon Berard, 28 rue Laennec, Lyon Cedex 08, 69373, France
    BMC Cancer 12:603. 2012
    ....
  31. doi request reprint [Antihormonal therapy in breast cancer and mTOR inhibitors]
    Pierre Etienne Heudel
    Centre Leon Berard, Oncologie Médicale, Lyon, France
    Bull Cancer 98:1431-7. 2011
    ....
  32. doi request reprint ERCC5/XPG, ERCC1, and BRCA1 gene status and clinical benefit of trabectedin in patients with soft tissue sarcoma
    Antoine Italiano
    Department of Medical Oncology, Institut Bergonie, Bordeaux, France
    Cancer 117:3445-56. 2011
    ....
  33. doi request reprint Randomized phase II trial of everolimus in combination with tamoxifen in patients with hormone receptor-positive, human epidermal growth factor receptor 2-negative metastatic breast cancer with prior exposure to aromatase inhibitors: a GINECO study
    Thomas Bachelot
    Département de Cancérologie Médicale et Unité INSERM U590, Centre Leon Berard, 28 rue Laennec, 69373 Lyon Cedex 08, France
    J Clin Oncol 30:2718-24. 2012
    ..This analysis evaluated efficacy and safety of everolimus in combination with tamoxifen in patients with mBC resistant to aromatase inhibitors (AIs)...
  34. doi request reprint First-line endocrine therapy alone could be a reasonable treatment option for hormone-positive, HER2-positive metastatic breast cancer
    Julien Peron
    Centre Leon Berard, Department of Medical Oncology, 28, rue Laennec, 69008 Lyon, France
    Bull Cancer 99:E18-25. 2012
    ..Previously validated clinical practice guidelines recommending the use of endocrine therapy alone in first line might be changed...
  35. doi request reprint A phase II study of gefitinib for patients with advanced HER-1 expressing synovial sarcoma refractory to doxorubicin-containing regimens
    Isabelle Ray-Coquard
    Centre Léon Bérard and UJOMM H E Herriot, Lyon, France
    Oncologist 13:467-73. 2008
    ..Based on a report showing a specific overexpression of HER-1 in SyS, we investigated an HER-1 inhibitor, gefitinib, in refractory SyS...
  36. pmc Incidence of sarcoma histotypes and molecular subtypes in a prospective epidemiological study with central pathology review and molecular testing
    Françoise Ducimetière
    Universite de Lyon, Cancer Centre Léon Bérard, EA 4129, Lyon, France
    PLoS ONE 6:e20294. 2011
    ..The objective of the present population-based study was to determine this incidence in a European region (Rhone-Alpes) of six million inhabitants, based on a central pathological review of the cases...
  37. ncbi request reprint Persistence of medical change at implementation of clinical guidelines on medical practice: a controlled study in a cancer network
    Isabelle Ray-Coquard
    Centre Leon Berard, 28, rue Laennec, 69008 Lyon, France
    J Clin Oncol 23:4414-23. 2005
    ..In the present study, we evaluated the persistence of conformity to guidelines through a new medical audit...
  38. doi request reprint Is there a role for discontinuing imatinib in patients with advanced gastrointestinal stromal tumour?
    Jean Yves Blay
    Département de Médecine and Unité INSERM U590, Centre Leon Berard, Lyon, France
    Curr Opin Oncol 21:360-6. 2009
    ..In this setting, the optimal duration of treatment is not known, and it is generally considered that treatment should be given until progression or intolerance...
  39. doi request reprint Autocrine role for Gas6 with Tyro3 and Axl in leiomyosarcomas
    Hiba El Sayadi
    Pole des Sciences Cliniques and Centre de Recherche en Cancerologie de Lyon, INSERM UMR5286 Equipe 11, Centre Leon Berard, Lyon, France
    Target Oncol 8:261-9. 2013
    ..Leiomyosarcomas overexpress Tyro3. Gas6, a ligand of Tyro3, exerts an autocrine activities though Tyro3 and Axl in a subgroup of LMS...
  40. ncbi request reprint Epirubicin and paclitaxel (EPI-TAX regimen) for advanced ovarian cancer after failure of platinum-containing regimens
    Isabelle Ray-Coquard
    Centre Leon Berard, 28, rue Laennec, 69008, Lyon, France
    Gynecol Oncol 88:351-7. 2003
    ..We have assessed the feasibility and evaluated the tolerance of epirubicin (EPI) combined with paclitaxel (TAX) in heavily pretreated ovarian cancer patients...
  41. ncbi request reprint [Neoadjuvant chemotherapy and ovarian cancer]
    Isabelle Ray-Coquard
    Centre Leon Berard, Lyon
    Bull Cancer 93:669-76. 2006
    ..The strategy of neoadjuvant chemotherapy, followed by interval debulking surgery, should be confirmed in a prospective randomized trial. The EORTC55971 trial is currently addressing this issue...
  42. doi request reprint Bevacizumab and paclitaxel for breast cancer patients with central nervous system metastases: a case series
    Sana Intidhar Labidi
    Department of Medical Oncology, Centre Leon Berard, Laennec, France
    Clin Breast Cancer 9:118-21. 2009
    ....
  43. doi request reprint Management of rare ovarian cancers: the experience of the French website "Observatory for rare malignant tumours of the ovaries" by the GINECO group: interim analysis of the first 100 patients
    Isabelle Ray-Coquard
    Centre Leon Berard, SIS 4921, 28 rue Laennec, 69008 Lyon, France
    Gynecol Oncol 119:53-9. 2010
    ..We report the results of the first 100 patients with germ cell (GCT) and sex cord-stromal (SCT) tumours...
  44. doi request reprint [Targeted therapy of sarcomas]
    Philippe A Cassier
    Hopital Edouard Herriot, Service d Oncologie Medicale, Lyon, France
    Bull Cancer 95:963-74. 2008
    ..Together with the current development of numerous targeted therapies, these recent progress are the basis of tomorrow's personalised medicine for patients with soft tissue sarcoma...
  45. ncbi request reprint Quantitative and functional alterations of plasmacytoid dendritic cells contribute to immune tolerance in ovarian cancer
    Sana Intidhar Labidi-Galy
    Departments of Medical Oncology, Centre de Recherche en Cancérologie de Lyon, Centre Leon Berard, Lyon, France
    Cancer Res 71:5423-34. 2011
    ..Taken together, our findings indicate that both local and systemic dysfunction of pDC play a critical role in the progression of ovarian cancer via induction of immune tolerance...
  46. doi request reprint 2007 Standards, Options, and Recommendations: use of erythropoiesis-stimulating agents (ESA: epoetin alfa, epoetin beta, and darbepoetin) for the management of anemia in children with cancer
    Perrine Marec-Berard
    Department of Pediatrics, Hemato Oncologic Pediatric Institute, Lyon, France
    Pediatr Blood Cancer 53:7-12. 2009
    ..However, treatment decision must be made on a case-by-case basis and, when treatment is considered, the intravenous route must be preferred. The full French document is available at www.sor-cancer.fr...
  47. pmc Epidemiological evaluation of concordance between initial diagnosis and central pathology review in a comprehensive and prospective series of sarcoma patients in the Rhone-Alpes region
    Antoine Lurkin
    Centre Leon Berard, Lyon, France
    BMC Cancer 10:150. 2010
    ..We prospectively assessed the medical management of all patients diagnosed with sarcoma in a European region over a one-year period to identify the quantity of first diagnosis compared to central expert review (CER)...
  48. ncbi request reprint Primary ovarian borderline tumor in the inguinal lymph node
    Nicolas Carrabin
    Department of Surgical Oncology, Centre Leon Berard, Lyon, France
    Int J Gynecol Pathol 32:167-70. 2013
    ..Ectopic ovarian tissue can be observed in lymph node. We don't believe ectopic location of ovarian tissue increase the risk of neoplastic change...
  49. pmc Recombinant erythropoietin for the anaemia of patients with advanced Gastrointestinal Stromal Tumours (GIST) receiving imatinib: an active agent only in non progressive patients
    Florence Duffaud
    Centre Leon Berard, Department of Medecine, French Sarcoma Group GSF GETO, European Organisation for Research and Treatment of Cancer EORTC, University Claude Bernard Lyon I, Lyon, France
    Clin Sarcoma Res 2:11. 2012
    ..ABSTRACT: Recombinant erythropoietin for the anaemia of patients with advanced Gastrointestinal Stromal Tumours (GIST) receiving imatinib : an active agent only in non progressive patients...
  50. ncbi request reprint Lymphopenia: a new independent prognostic factor for survival in patients treated with whole brain radiotherapy for brain metastases from breast carcinoma
    Line Claude
    Department of Radiation Oncology, Hopital Edouard Herriot, Lyon, France
    Radiother Oncol 76:334-9. 2005
    ..To determine overall survival (OS) and independent prognostic factors in patients with brain metastases (BM) from breast cancer treated by whole brain radiotherapy (WBR)...
  51. pmc Sorafenib for patients with advanced angiosarcoma: a phase II Trial from the French Sarcoma Group (GSF/GETO)
    Isabelle Ray-Coquard
    Department of Medical Oncology, Centre Leon Berard, Lyon, France
    Oncologist 17:260-6. 2012
    ..We investigated the antitumor activity of sorafenib in patients with metastatic or advanced angiosarcomas in a phase II trial...
  52. doi request reprint Impact of a second opinion using expression and molecular analysis of FOXL2 for sex cord-stromal tumors. A study of the GINECO group & the TMRO network
    Denis Maillet
    Centre Leon Berard, Lyon, France Université Claude Bernard Lyon1 Université de Lyon, Lyon, France
    Gynecol Oncol 132:181-7. 2014
    ..This study aims to assess the benefit of an algorithm incorporating these new tools for a better diagnosis and classification of SCSTs..
  53. doi request reprint Predicting everolimus treatment efficacy in patients with advanced endometrial carcinoma: a GINECO group study
    Olivier Tredan
    Department of Medical Oncology, Leon Berard Cancer Center, 28 rue Laennec, Lyon, 69008, France
    Target Oncol 8:243-51. 2013
    ..However, endometrial cancer patients with K-RAS mutations do not seem to derive benefit from everolimus treatment...
  54. pmc Factors of interrupting chemotherapy in patients with Advanced Non-Small-Cell Lung Cancer
    Rhizlane Belbaraka
    Department of Medical Oncology, Centre Leon Berard, 28 rue Laennec, Lyon 69008, France
    BMC Res Notes 3:164. 2010
    ..In this prospective study, which included 45 patients, we identified clinical and biological variables as outcome predictors in metastatic Non-Small Cell lung cancer after first line chemotherapy were identified...
  55. ncbi request reprint Medical practices and cancer care networks: examples in oncology
    Isabelle Ray-Coquard
    Centre Leon Berard, 28, rue Laennec, 69008 Lyon, France
    Bull Cancer 93:E13-20. 2006
    ..This article provides a state-of-the-art overview of the subject, notably in the domain of oncology where substantial advances are being made...
  56. doi request reprint An increasing role for trabectedin in gynecological cancers: efficacy in uterine sarcomas
    Isabelle Ray-Coquard
    Centre Leon Berard, Lyon, France
    Int J Gynecol Cancer 21:S3-5. 2011
    ..These results are being confirmed in a current prospective phase II study in first-line uterine leiomyosarcoma combining trabectedin with doxorubicin...
  57. ncbi request reprint Low serum albumin levels and liver metastasis are powerful prognostic markers for survival in patients with carcinomas of unknown primary site
    Pascal Seve
    Department of Internal Medicine, Hotel Dieu, Hospices Civils de Lyon, Lyon, France
    Cancer 107:2698-705. 2006
    ..The authors investigated how lymphopenia and low serum albumin levels correlate with the prognosis of patients with carcinoma of unknown primary (CUP)...
  58. doi request reprint The clinician's perspective on sarcoma pathology reporting: impact on treatment decisions?
    Jean Yves Blay
    1Department of Medecine, Centre Léon Bérard 2Unité INSERM 1052, CRCL Eq 11 Centre Léon Bérard 3Université Claude Bernard Lyon 1, Lyon, France
    Pathology 46:121-5. 2014
    ..Molecular grade is a research tool with potentially high utility, and requires further evaluation and validation in prospective clinical trials...
  59. ncbi request reprint CD4 lymphopenia as a risk factor for febrile neutropenia and early death after cytotoxic chemotherapy in adult patients with cancer
    Christophe Borg
    INSERM U590, Centre Leon Berard, Lyon, France
    Cancer 101:2675-80. 2004
    ..Lymphopenia is frequently observed in patients with cancer and correlates with the risk of febrile neutropenia and early death after chemotherapy. The phenotype of the depleted lymphocyte populations was investigated in the current study...
  60. ncbi request reprint [Targeted treatment of cancers with imatinib mesylate (STI571, Gleevec): results of Asco 2002]
    Isabelle Ray-Coquard
    INSERM U 453, Centre Leon Berard, 28, rue Laennec, 69008 Lyon, France
    Bull Cancer 89:567-9. 2002
  61. doi request reprint Do our current clinical trial designs help to guide clinical practice?
    Jean Yves Blay
    From the Department of Medicine, Centre Leon Berard, Lyon, France Unité INSERM 1052, Centre Leon Berard, Lyon, France Université Claude Bernard Lyon, Lyon, France
    Am Soc Clin Oncol Educ Book 2013:381-5. 2013
    ..This paper discusses the limitations of previous clinical trial designs to guide clinical practice in this complex context...
  62. ncbi request reprint [Adjuvant therapy for breast cancer patients: treatment decision tree from a French cancer network]
    Thomas Bachelot
    Centre Leon Berard, 28, rue Laennec, 69373 Lyon Cedex 08, France
    Bull Cancer 89:897-903. 2002
    ..However, due to the subjectivity of risk/benefit estimations, patients themselves should become more involved in the decision-making process...